

Sunil Badve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1850510/publications.pdf>

Version: 2024-02-01

131
papers

14,811
citations

76031

42
h-index

25983

112
g-index

134
all docs

134
docs citations

134
times ranked

17635
citing authors

#	ARTICLE	IF	CITATIONS
1	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
2	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
3	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	13.9	1,146
4	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. <i>Journal of Clinical Oncology</i> , 2014, 32, 2959-2966.	0.8	1,080
5	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 907-922.	1.2	697
6	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011, 24, 157-167.	2.9	545
7	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	2.4	530
8	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
9	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
10	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 2013, 105, 701-710.	3.0	442
11	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
12	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
13	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
14	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270
15	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
16	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	0.8	223
17	FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival. <i>Clinical Cancer Research</i> , 2007, 13, 4415-4421.	3.2	220
18	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201.	2.9	205

#	ARTICLE	IF	CITATIONS
19	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
20	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	3.4	183
21	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	0.6	177
22	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	3.4	161
23	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
24	Breast-cancer stem cells—beyond semantics. <i>Lancet Oncology</i> , The, 2012, 13, e43-e48.	5.1	137
25	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
26	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	2.3	109
27	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	4.3	108
28	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
29	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	3.4	100
30	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
31	Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. <i>Human Pathology</i> , 1998, 29, 915-923.	1.1	81
32	Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. <i>Journal of Clinical Pathology</i> , 2009, 62, 6-12.	1.0	74
33	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> – <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	2.1	74
34	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	1.6	74
35	Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. <i>Journal of Thoracic Oncology</i> , 2018, 13, 436-446.	0.5	70
36	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	2.9	68

#	ARTICLE	IF	CITATIONS
37	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.	3.2	65
38	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
39	Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers. <i>Scientific Reports</i> , 2015, 5, 8765.	1.6	55
40	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 4691.	1.6	53
41	Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. <i>Oncotarget</i> , 2015, 6, 12682-12696.	0.8	52
42	NF- κ B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. <i>Cell Death and Disease</i> , 2015, 6, e1608-e1608.	2.7	48
43	Splicing factor <i>ESRP1</i> controls ER ⁺ positive breast cancer by altering metabolic pathways. <i>EMBO Reports</i> , 2019, 20, .	2.0	48
44	A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. <i>British Journal of Cancer</i> , 2016, 114, 477-484.	2.9	47
45	Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues. <i>Scientific Reports</i> , 2019, 9, 5624.	1.6	45
46	Ductal carcinoma in situ of breast: update 2019. <i>Pathology</i> , 2019, 51, 563-569.	0.3	43
47	Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1082-1082.	0.8	43
48	Single-cell heterogeneity in ductal carcinoma in situ of breast. <i>Modern Pathology</i> , 2018, 31, 406-417.	2.9	41
49	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 867-871.	3.0	41
50	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2139-2149.	1.9	40
51	Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 375-384.	1.1	37
52	Molecular Analysis of Thymoma. <i>PLoS ONE</i> , 2012, 7, e42669.	1.1	37
53	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. <i>Modern Pathology</i> , 2015, 28, 1415-1427.	2.9	36
54	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33

#	ARTICLE	IF	CITATIONS
55	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
56	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
57	Small Cells in Hepatoblastoma Lack "Oval" Cell Phenotype. <i>Modern Pathology</i> , 2003, 16, 930-936.	2.9	28
58	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. <i>Modern Pathology</i> , 2015, 28, 677-685.	2.9	28
59	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1005-1005.	0.8	28
60	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3989-4001.	0.4	27
61	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 87.	2.2	26
62	Histologic Distribution and Biochemical Properties of Î± ₁ -Microglobulin in Human Placenta. <i>American Journal of Reproductive Immunology</i> , 1999, 41, 52-60.	1.2	25
63	Expression of Invariant Chain (CD 74) and Major Histocompatibility Complex (MHC) Class II Antigens in the Human Fetus1. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 473-482.	1.3	25
64	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. <i>JAMA Oncology</i> , 2019, 5, 1036.	3.4	23
65	Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1000-1000.	0.8	23
66	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	0.8	23
67	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. <i>Scientific Reports</i> , 2020, 10, 12123.	1.6	22
68	Breast Implant Capsule-Associated Squamous Cell Carcinoma: Report of 2 Patients. <i>International Journal of Surgical Pathology</i> , 2022, 30, 900-907.	0.4	22
69	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	3.2	21
70	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. <i>Frontiers in Oncology</i> , 2021, 11, 736620.	1.3	19
71	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
72	Biomarkers for breast cancer stem cells: the challenges ahead. <i>Biomarkers in Medicine</i> , 2011, 5, 661-671.	0.6	17

#	ARTICLE	IF	CITATIONS
73	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. <i>Breast Cancer Research</i> , 2019, 21, 114.	2.2	17
74	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	3.6	17
75	Differential subcellular expression of protein kinase C beta1 in breast cancer: correlation with breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 327-335.	1.1	16
76	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
77	Ductal lavage and its histopathologic basis: A cautionary tale. <i>Diagnostic Cytopathology</i> , 2004, 30, 166-171.	0.5	13
78	EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor β . <i>Journal of Clinical Pathology</i> , 2013, 66, 1051-1057.	1.0	13
79	Tumor Heterogeneity in Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2015, 22, 294-302.	2.4	12
80	Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1019-1019.	0.8	12
81	Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. <i>PLoS ONE</i> , 2018, 13, e0204658.	1.1	11
82	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. <i>British Journal of Cancer</i> , 2021, 124, 1150-1159.	2.9	11
83	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 633-645.	1.2	9
84	The Birth of an Adenoid Cystic Carcinoma. <i>International Journal of Surgical Pathology</i> , 2015, 23, 26-27.	0.4	9
85	TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1118-1119.	3.0	8
86	EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 17-26.e8.	1.1	7
87	EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. <i>Breast</i> , 2019, 43, 74-80.	0.9	7
88	Tumour-infiltrating lymphocytes in ductal carcinoma <i>in situ</i> (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score. <i>Histopathology</i> , 2020, 77, 749-759.	1.6	7
89	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. <i>Cancers</i> , 2021, 13, 315.	1.7	7
90	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 505-505.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. <i>Oncotarget</i> , 2021, 12, 1178-1186.	0.8	6
92	Is conservative management of ductal carcinoma in situ risky?. <i>Npj Breast Cancer</i> , 2022, 8, 55.	2.3	6
93	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.	3.2	6
94	Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy. <i>Journal of Biomedical Optics</i> , 2015, 20, 096016.	1.4	5
95	10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1021-1021.	0.8	5
96	Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. <i>Endocrinology</i> , 2022, 163, .	1.4	5
97	The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. <i>Oncotarget</i> , 2017, 8, 108534-108547.	0.8	4
98	Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 509-516.	1.1	4
99	Protein Profiling of Breast Cancer for Treatment Decision-Making. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 73-81.	1.8	4
100	Equivalency of RT-PCR and immunohistochemistry: fact or factoid. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 145-147.	1.1	3
101	Does Tumor Size Trump Biology?. <i>Clinical Breast Cancer</i> , 2010, 10, 111-112.	1.1	3
102	Malignant Brenner Tumor Mimicking a Primary Squamous Cell Carcinoma of the Cervix. <i>Gynecologic Oncology</i> , 1999, 74, 487-490.	0.6	2
103	Promise of computational systems biology for cancer clinical trials: the voyage to be realized?. <i>Personalized Medicine</i> , 2010, 7, 129-131.	0.8	2
104	AJCC 8 th editionâ€”A step forward. <i>Breast Journal</i> , 2020, 26, 1263-1264.	0.4	2
105	Thymic Carcinomas and Second Malignancies: A Single-Center Review. <i>Cancers</i> , 2021, 13, 2472.	1.7	2
106	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12010-12010.	0.8	2
107	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
108	Opportunistic infections in a patient with HIV and thymoma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 413-415.	2.0	1

#	ARTICLE	IF	CITATIONS
109	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz051.	1.4	1
110	Next-generation sequencing of thymic malignancies.. Journal of Clinical Oncology, 2012, 30, 7032-7032.	0.8	1
111	INDUCT: A risk score to predict relapse in estrogen-receptor-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11063-11063.	0.8	1
112	A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 7106-7106.	0.8	1
113	D-Dimer Measurements Unhelpful for Ruling In DIC. Laboratory Medicine, 2000, 31, 383-386.	0.8	0
114	FOXA1 Expression in Urothelial Carcinoma of the Renal pelvis. American Journal of Clinical Pathology, 2012, 138, A296.2-A296.	0.4	0
115	Correlation of FOXA1 expression with Oncotype Dx recurrence scores. Journal of Clinical Oncology, 2009, 27, 11058-11058.	0.8	0
116	Factors affecting survival of patients with Masaoka stage IV thymic epithelial tumors (TET).. Journal of Clinical Oncology, 2012, 30, 7107-7107.	0.8	0
117	In silico identification of an epithelial core signature in human tumors.. Journal of Clinical Oncology, 2012, 30, 10628-10628.	0.8	0
118	Factors influencing outcome in thymic epithelial tumors (TET).. Journal of Clinical Oncology, 2012, 30, 7108-7108.	0.8	0
119	A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 68-68.	0.8	0
120	A gene signature to determine metastatic behavior in thymic carcinoma.. Journal of Clinical Oncology, 2013, 31, 7605-7605.	0.8	0
121	A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTR) in esophageal adenocarcinoma (EC).. Journal of Clinical Oncology, 2014, 32, 51-51.	0.8	0
122	RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146.. Journal of Clinical Oncology, 2014, 32, 1002-1002.	0.8	0
123	Prognostic ability of CD44 expression in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11062-11062.	0.8	0
124	Prediction of late relapse in patients with estrogen-receptor-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11065-11065.	0.8	0
125	A proprietary multi-analyte test to predict neoadjuvant treatment response for esophageal and rectal adenocarcinoma patients.. Journal of Clinical Oncology, 2014, 32, 4085-4085.	0.8	0
126	Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130.. Journal of Clinical Oncology, 2014, 32, 7594-7594.	0.8	0

#	ARTICLE	IF	CITATIONS
127	CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 598-598.	0.8	0
128	ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.. Journal of Clinical Oncology, 2019, 37, 599-599.	0.8	0
129	Fibroblastic sarcomas of the mediastinum. Mediastinum, 2020, 4, 26-26.	0.6	0
130	Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician's choice for patients with residual triple negative breast cancer. Cancer Research, 2022, 82, PD9-10-PD9-10.	0.4	0
131	Deconvolution of gene expression for microenvironmental cell types in thymomas.. Journal of Clinical Oncology, 2022, 40, e20623-e20623.	0.8	0